Wilson Z. Shou

Wilson Z. Shou

Auto-generated profile, based on publicly available information

Wilson Z. Shou

Bristol-Myers Squibb, Wallingford, CT, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
DZDonglu Zhang
Donglu Zhang
KHKan He
Kan He
JHJohn J. Herbst
John J. Herbst
JKJanet Kolb
Janet Kolb
WSWilson Shou
Wilson Shou
WHW. Griffith Humphreys
W. Griffith Humphreys
The studies reported here were conducted to investigate the transport characteristics of apixaban (1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide) and to understand the impact of transporters on apixaban distribution and disposition. In human permeability glycoprotein (P-gp)- and breast cancer resistance protein (BCRP)-cDNA–transfected cell monolayers as well as Caco-2 cell monolayers, the apparent efflux ratio of basolateral-to-apical (PcB-A) versus apical-to-basolateral permeability (PcA-B) of apixaban was >10. The P-gp- and BCRP-facilitated transport of apixaban was concentration- and time-dependent and did not show saturation over a wide range of concentrations (1–100 μM). The efflux transport of apixaban was also demonstrated by the lower mucosal-to-serosal permeability than that of the serosal-to-mucosal direction in isolated rat jejunum segments. Apixaban did not inhibit digoxin transport in Caco-2 cells. Ketoconazole decreased the P-gp-mediated apixaban efflux in Caco-2 and the P-gp-cDNA–transfected cell monolayers, but did not affect the apixaban efflux to a meaningful extent in the BCRP-cDNA–transfected cell monolayers. Coincubation of a P-gp inhibitor (ketoconazole or cyclosporin A) and a BCRP inhibitor (Ko134) provided more complete inhibition of apixaban efflux in Caco-2 cells than separate inhibition by individual inhibitors. Naproxen inhibited apixaban efflux in Caco-2 cells but showed only a minimal effect on apixaban transport in the BCRP-transfected cells. Naproxen was the first nonsteroidal antiinflammatory drug that was demonstrated as a weak P-gp inhibitor. These results demonstrate that apixaban is a substrate for efflux transporters P-gp and BCRP, which can help explain its low brain penetration, and low fetal exposures and high milk excretion in rats.


30 March 2001 in Journal of Chromatography B: Biomedical Sciences and Applications
Verified
Journal Article
Closed access
WNWeng Naidong
Weng Naidong
WSWilson Shou
Wilson Shou
YCYu-Luan Chen
Yu-Luan Chen
XJXiangyu Jiang
Xiangyu Jiang

1 June 2020 in Journal of Pharmaceutical Analysis
Verified
Journal Article
Open access
WSWilson Z. Shou
Wilson Z. Shou
During the last decade high-throughput in vitro absorption, distribution, metabolism and excretion (HT-ADME) screening has become an essential part of any drug discovery effort of synthetic molecules. The conduct of HT-ADME screening has been “industrialized” due to the extensive development of software and automation tools in cell culture, assay incubation, sample analysis and data analysis. The HT-ADME assay portfolio continues to expand in emerging areas such as drug-transporter interactions, early soft spot identification, and ADME screening of peptide drug candidates. Additionally, thanks to the very large and high-quality HT-ADME data sets available in many biopharma companies, in silico prediction of ADME properties using machine learning has also gained much momentum in recent years. In this review, we discuss the current state-of-the-art practices in HT-ADME screening including assay portfolio, assay automation, sample analysis, data processing, and prediction model building. In addition, we also offer perspectives in future development of this exciting field.

7 March 2001 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
WSWilson Z. Shou
Wilson Z. Shou
XJXiangyu Jiang
Xiangyu Jiang
BBBrian D. Beato
Brian D. Beato
WNWeng Naidong
Weng Naidong

25 September 2002 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
WNWeng Naidong
Weng Naidong
WSWilson Z. Shou
Wilson Z. Shou
TAThomas Addison
Thomas Addison
SMSaber Maleki
Saber Maleki
XJXiangyu Jiang
Xiangyu Jiang